May 9 (Reuters) - Commonwealth Bank of Australia (CBA) :
- WE REMAIN POSITIVE ON THE MEDIUM-TERM OUTLOOK FOR AUSTRALIAN ECONOMY
- QTRLY UNAUDITED CASH NPAT OF A$2.6 BILLION VERSUS A$2.4 BILLION REPORTED YEAR AGO
- QTRLY UNAUDITED STATUTORY NPAT OF A$2.6 BILLION VERSUS A$2.3 BILLION REPORTED YEAR AGO
- AS AT MARCH 31, CET 1 RATIO OF 12.1%
- QTRLY NET INTEREST INCOME WAS 2% LOWER VERSUS 1H23 QUARTER AVERAGE
- QTRLY LOAN IMPAIRMENT EXPENSE A$223 MILLION
- MANY OF OUR CUSTOMERS ARE FEELING THE STRAIN OF HIGHER INTEREST RATES AND THE RISING COST OF LIVING
- QTRLY OPERATING EXPENSES EX REMEDIATION REDUCED BY 1% VERSUS 1H23 QUARTER AVERAGE
- IN QUARTER PORTFOLIO CREDIT QUALITY REMAINED SOUND, WITH CREDIT PROVISIONS INCREASING SLIGHTLY TO FURTHER STRENGTHEN OUR BALANCE SHEET POSITION
- HOUSEHOLD DEPOSITS ALSO GREW A$6.2 BILLION IN THE QUARTER
- AS HIGHER INTEREST RATES IMPACT THE AUSTRALIAN ECONOMY IN PERIOD AHEAD, EXPECT ECONOMIC GROWTH TO CONTINUE TO MODERATE
- IN QUARTER HOME LOAN ARREARS REMAINED LOW AT 0.44%
- CBA - AS AT MARCH 31, TROUBLESOME AND IMPAIRED ASSETS WERE HIGHER AT A$6.7 BILLION
- BALANCE SHEET SETTINGS REMAINED STRONG IN THE QUARTER
- EXPECT TO SEE FURTHER INCREASES IN ARREARS RATES AS FULL EFFECTS OF INTEREST RATE INCREASES ARE BORNE BY BORROWERS IN MONTHS AHEAD
- AS AT 8 MAY 2023, GROUP HAD COMPLETED APPROXIMATELY A$2 BILLION OF A$3 BILLION SHARE BUY-BACK
- BALANCE SHEET STRENGTH POSITIONS US WELL TO CONTINUE TO SUPPORT CUSTOMERS AND EXTEND CREDIT REQUIRED TO GROW AUSTRALIAN ECONOMY
- DESPITE CHALLENGING GLOBAL ECONOMIC OUTLOOK, AUSTRALIA IS RELATIVELY WELL POSITIONED GIVEN STRENGTH OF OUR BANKING SYSTEM
- LOWER NET INTEREST MARGINS FROM COMPETITIVE PRESSURES DURING QUARTER
- Forums
- ASX - By Stock
- News: CBA CBA Posts Unaudited Cash NPAT of A$2.6 Billion For Qtr
CBA
commonwealth bank of australia.
Add to My Watchlist
2.81%
!
$185.36

May 9 (Reuters) - Commonwealth Bank of Australia (CBA) : WE...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$185.36 |
Change
-5.350(2.81%) |
Mkt cap ! $310.1B |
Open | High | Low | Value | Volume |
$190.50 | $191.06 | $185.36 | $367.6M | 1.971M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 4521 | $185.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$185.88 | 70 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15 | 185.360 |
18 | 4516 | 185.000 |
1 | 50 | 184.950 |
4 | 383 | 184.500 |
1 | 15 | 184.400 |
Price($) | Vol. | No. |
---|---|---|
185.880 | 70 | 1 |
186.090 | 50 | 1 |
187.000 | 300 | 1 |
187.400 | 5 | 1 |
187.600 | 58 | 1 |
Last trade - 16.11pm 27/06/2025 (20 minute delay) ? |
Featured News
CBA (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online